Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc., listed under ticker DECA, filed an 8-K current report with the SEC on June 25, 2026, disclosing a material corporate development. The company operates in the pharmaceutical sector and reached the public markets through a SPAC business combination, making it one of the healthcare-focused de-SPAC entities actively tracked across the industry. The filing, bearing accession number 0001193125-26-283007, reflects the company's continuing disclosure obligations as a publicly traded combined entity under the DECA ticker. Semnur Pharmaceuticals is positioned in the specialty therapeutics space, a sector that has drawn consistent SPAC deal activity in recent years. Sign up at SpacDesk for full filing history, sponsor details, and deal timelines on DECA and the broader SPAC market.